Also known as Jemperli.
76% of evaluable patients had no detectable cancer after dostarlimab monotherapy; responders show no recurrences after more than two years; safety consistent with known profile.
First FDA‑approved immunotherapy for this biomarker-defined rectal cancer; AZUR-1 shows high sustained clinical complete response rates and no recurrences among responders.
More than 20 abstracts across lung, gynaecological and gastrointestinal cancers, including positive Ris‑Rez ES‑SCLC activity, Mo‑Rez durable responses in platinum‑resistant ovarian cancer, and Jemperli complete responses in MSI‑H rectal cancer.
FDA sets PDUFA Feb 2027 for Jemperli’s supplemental filing based on AZUR‑1 data showing sustained 12‑month complete responses, potentially avoiding chemo, radiation and surgery.
Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.
Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.
